Kronos Bio was founded in 2017 and is dedicated to the discovery and development of new therapies for cancer.  The company utilizes a novel approach to high-throughput screening of chemical libraries in order to identify binders or inhibitors of complex protein interactions, with a focus on modulating transcription factors and other challenging targets that have historically been considered ‘undruggable.’